⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

April 10, 2024EClinicalMedicineOpen Access

Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England

Freja Kirsebom Nick Andrews Julia Stowe Gavin Dabrera Mary Ramsay Jamie Lopez Bernal

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

The Sanofi/GSK AS03-adjuvanted (VidPrevtyn Beta) vaccine and the Pfizer-BioNTech mRNA (Comirnaty Original/Omicron BA.4-5) bivalent vaccine were offered to adults aged 75 years and over in England from 3rd April 2023. This is the first time an adjuvanted COVID-19 vaccine has been administered as part of a UK COVID-19 vaccination programme. In clinical trials, antibody levels generated were comparable with mRNA vaccines but there are no real-world data on the effectiveness or duration of protection.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kirsebom et al. (2024) studied this question.

synapsesocial.com/papers/68e6f97db6db64358767453f https://doi.org/10.1016/j.eclinm.2024.102587

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged 50+ in England: observational matched cohort study using OpenSAFELYCohort Study · 2026 · 3 citations
2Comparative safety and effectiveness of Pfizer BA.4-5 versus Sanofi during the spring 2023 COVID-19 booster vaccination programme in England: a matched cohort study in OpenSAFELY-TPP2024 · 1 citations
3Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study2024 · 37 citations
4Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study2024 · 35 citations
5Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccinesRCT · 2022 · 26 citations
6Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States2024 · 11 citations
7Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 TrialHuman Clinical Trial · 2024 · 42 citations
8Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UKOriginal Research · 2021 · 807 citations
9A review of global health architecture reform efforts—navigating between reform and fragmentationEClinicalMedicine · 2026
10An explainable artificial intelligence system for prognostic assessment and decision support in diabetic foot ulcer care: a multicentre derivation and validation study with prospective randomised evaluationEClinicalMedicine · 2026

More from EClinicalMedicine

More from Imperial College London

More from London School of Hygiene & Tropical Medicine

More from NIHR Imperial Biomedical Research Centre

More from UK Health Security Agency